Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the …

…, LA Teoh, SA Fischkoff, EK Chartash - Arthritis & …, 2003 - Wiley Online Library
Objective To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal
tumor necrosis factor α antibody, in combination with methotrexate (MTX) in patients with …

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active …

…, LS Teoh, SA Fischkoff, EK Chartash - Arthritis & …, 2004 - Wiley Online Library
Objective Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates
inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We …

[HTML][HTML] PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma

…, L Annamalai, S Berry, EK Chartash… - … England Journal of …, 2016 - Mass Medical Soc
Background Merkel-cell carcinoma is an aggressive skin cancer that is linked to exposure to
ultraviolet light and the Merkel-cell polyomavirus (MCPyV). Advanced Merkel-cell …

Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid …

…, D Compagnone, SA Fischkoff, EK Chartash - The Journal of …, 2003 - jrheum.org
OBJECTIVE: This study, known as STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis),
evaluated the safety and efficacy of adalimumab (Humira), a fully human monoclonal …

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid …

…, GR Granneman, SA Fischkoff, EK Chartash - Clinical …, 2003 - Elsevier
Background: Because traditional therapies for rheumatoid arthritis (RA) such as methotrexate
(MTX) do not produce an adequate response in many patients, newer therapies that block …

Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study

…, DE Furst, AF Kavanaugh, EK Chartash… - Annals of the …, 2006 - ard.bmj.com
Objective: To evaluate the efficacy and safety of adalimumab plus methotrexate (MTX) given
for up to 4 years in patients with active, longstanding rheumatoid arthritis. Methods: Patients …

Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a …

…, RG Langley, A Menter, EK Chartash… - Archives of …, 2008 - jamanetwork.com
… Analysis and interpretation of data: Kimball, Langley, Chartash, and Valdes. Drafting of
the manuscript: Chartash. Critical revision of the manuscript for important intellectual content: …

Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial

…, A Fichtner, M de Longueville, EK Chartash - The Journal of …, 2014 - jrheum.org
Objective. To evaluate the humoral immune response to pneumococcal and influenza
vaccination in adults with rheumatoid arthritis (RA) receiving certolizumab pegol (CZP). Methods. …

Cardiac manifestations of the antiphospholipid syndrome

SD Kaplan, EK Chartash, RA Pizzarello, RA Furie - American heart journal, 1992 - Elsevier
The antiphospholipid syndrome has been associated with multiple cardiac abnormalities.
The earliest reports were of valvular disease, including verrucous endocarditis, as well as …

Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome

EK Chartash, DM Lans, SA Paget, T Qamar… - The American journal of …, 1989 - Elsevier
… Requests for reprints should be addressed to Elliot K. Chartash, MD, The Hospital for
Special Surgery, 535 East 70th Street, New York, New York 10021. Manuscript submitted Sep…